Intuitive Surgical (NASDAQ:ISRG) Trading Down 0.2% – Time to Sell?

Intuitive Surgical, Inc. (NASDAQ:ISRG) dropped 0.2% during trading on Thursday . The stock traded as low as $586.63 and last traded at $589.47. Approximately 235,658 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 1,880,671 shares. The stock had previously closed at $590.90.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Erste Group Bank upgraded shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Tuesday, November 19th. Raymond James upped their price target on Intuitive Surgical from $560.00 to $688.00 and gave the company an “outperform” rating in a research report on Friday, January 24th. Truist Financial increased their target price on Intuitive Surgical from $640.00 to $666.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. Stifel Nicolaus lifted their price objective on Intuitive Surgical from $525.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Finally, Evercore ISI lifted their target price on Intuitive Surgical from $490.00 to $530.00 in a research report on Monday, January 27th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus target price of $613.10.

Intuitive Surgical Stock Down 0.3 %

The firm has a market cap of $209.90 billion, a PE ratio of 91.93, a price-to-earnings-growth ratio of 5.51 and a beta of 1.39. The stock has a 50 day moving average price of $553.03 and a two-hundred day moving average price of $512.59.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of Intuitive Surgical stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $539.00, for a total transaction of $202,664.00. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,967,734. The trade was a 6.39 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Jamie Samath sold 94 shares of the firm’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $571.11, for a total transaction of $53,684.34. Following the transaction, the chief financial officer now directly owns 2,630 shares of the company’s stock, valued at approximately $1,502,019.30. This trade represents a 3.45 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,843 shares of company stock valued at $15,357,560. Insiders own 0.80% of the company’s stock.

Hedge Funds Weigh In On Intuitive Surgical

Several institutional investors and hedge funds have recently modified their holdings of the stock. Berbice Capital Management LLC purchased a new stake in Intuitive Surgical in the 4th quarter worth approximately $26,000. BankPlus Trust Department purchased a new stake in shares of Intuitive Surgical during the 4th quarter worth about $28,000. Godsey & Gibb Inc. increased its stake in shares of Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 35 shares in the last quarter. Kohmann Bosshard Financial Services LLC purchased a new position in Intuitive Surgical during the fourth quarter worth approximately $31,000. Finally, MidAtlantic Capital Management Inc. acquired a new position in shares of Intuitive Surgical during the 3rd quarter worth approximately $33,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.